IDEXX Laboratories, Inc. (IDXX)
Market Cap | 35.48B |
Revenue (ttm) | 3.84B |
Net Income (ttm) | 866.24M |
Shares Out | 81.88M |
EPS (ttm) | 10.36 |
PE Ratio | 41.83 |
Forward PE | 37.15 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 600,284 |
Open | 430.01 |
Previous Close | 433.00 |
Day's Range | 428.75 - 434.48 |
52-Week Range | 404.74 - 583.39 |
Beta | 1.36 |
Analysts | Buy |
Price Target | 545.29 (+25.85%) |
Earnings Date | Oct 31, 2024 |
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnos... [Read more]
Financial Performance
In 2023, IDEXX Laboratories's revenue was $3.66 billion, an increase of 8.72% compared to the previous year's $3.37 billion. Earnings were $845.04 million, an increase of 24.44%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price forecast is $545.29, which is an increase of 25.85% from the latest price.
News
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participan...
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating pr...
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68.
IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow
IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners.
IDEXX Laboratories Announces Third Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company repor...
IDEXX Laboratories to Release 2024 Third Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 third quarter results for Thursday, Octo...
IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and ...
IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near fu...
Animal Health Firm Idexx's Robust Business Model Bolsters Position Despite Slower Growth, Says Analyst
Tuesday, Idexx Laboratories Inc IDXX reported second-quarter adjusted EPS of $3.02, up 15% year-over-year, beating the consensus of $2.88.
IDEXX Laboratories, Inc. (IDXX) Q2 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants...
IDEXX Laboratories Announces Second Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company rep...
The Final Peak Week Of The Q2 Season Begins Amid Souring Economic Data
This marks the last peak week of the Q2 earnings season with 3,908 companies expected to report. Earnings have come in better-than-expected, but tend to be overshadowed by economic data. Outlier earni...
IDEXX Laboratories Announces Time Change for 2024 Second Quarter Financial Results Conference Call
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will now host its 2024 second quarter conference call and webcast at 9:00 am E...
IDEXX Releases 2023 Corporate Responsibility Report, Highlighting Progress Against Its Goals
WESTBROOK, Maine , July 30, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today published its 2023 Corporate Responsibility Report "Enhanc...
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing...
IDEXX Laboratories to Release 2024 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, Augu...
IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minut...
IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financia...
IDEXX Labs cuts 2024 revenue forecast on lagging vet visits, strong dollar
IDEXX Laboratories lowered its annual sales forecast after missing quarterly estimates on Wednesday, as the animal diagnostic equipment maker expects a hit from a slowdown in veterinary clinic visits ...
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company repor...
How to trade Fed news, plus stocks to consider
The Federal Reserve has entered a two-day meeting that will end with an announcement about its decision regarding interest rates. In the meantime, debate on Wall Street has been raging over how, when,...
IDEXX Laboratories to Release 2024 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May...
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am ...
IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect
Initial Vello Users Show an Average 19% Reduction in No-Show Rate, Enabling More Clinical Visits WESTBROOK, Maine , Feb. 15, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global lead...
IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript
IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript